Dexamethasone-Darnitsa is a synthetic adrenal hormone (corticosteroid) with a glucocorticoid action. It exerts anti-inflammatory and immunosuppressive effects and also influences the energy metabolism, glucose metabolism, and (via negative feedback) the secretion of hypothalamic releasing factor and pituitary trophic hormone.
Diagnostic examination of adrenal hyperfunction; trichinosis with neurological symptoms or myocardial trichinosis; tuberculous meningitis with subarachnoid obstruction or threat of obstruction (in combination with the appropriate tuberculosis treatment).
The dose of the drug should be determined on an individual basis, considering the patient's disease, predicted treatment duration, tolerability of glucocorticosteroids, and response of the body.
The recommended initial dose is 0.75–9 mg daily depending on the diagnosis. The starting doses of dexamethasone should be used until a clinical response is achieved, then the dose should be gradually decreased to the minimum clinically effective dose. If high-dose oral treatment lasts for more than several days, the dose should be gradually decreased for several more days or even for a more prolonged period (usually by 0.5 mg every 3 days). The maintenance dose is usually 2–4.5 mg per day. The daily dose can be divided in 2–4 single doses. The maximum daily dose is usually 15 mg, minimum effective dose is 0.5–1 mg per day. In the treatment of multiple sclerosis exacerbations, the daily dose can be 30 mg of dexamethasone for the first week of treatment, with further doses between 4 mg and 12 mg every other day for 1 month.
During prolonged treatment with high oral doses, it is recommended to take dexamethasone during meals and use antacids between meals.